🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Why Are Women Still Being Left Behind in Heart Failure Care? Join us Monday, May 12th at 7:00 PM CST for the first session of the WiTMCS #AHF Therapies in Women Webinar Series Cindy M. Martin Eileen Hsich #SharonBethLarson Aditi Nayak

🚨We're Hiring! @HopkinsHeart Umapathi Lab Johns Hopkins Medicine seeking a senior post-doc (1 yr, fully funded) to lead cutting-edge, translational research in cardiac iPSC, metabolism, O-GlcNAc & heart failure 🔬 Apply now! 🙏Re-Post😊 #CardioResearch #PostdocJobs #HeartFailure

🚨 Calling all #HeartFailure friends and colleagues Our 1⃣st Devices in Heart Failure day at HFSA 🔬Mechanisms,💡Implementation, 🖐️Hands on 📅 Sep 26 Minneapolis Details➡️ hfsa.org/asm/hfsa-devic… Special Events:⭐️Trial Tinder and ♥️Heart Tank Apply➡️hfsa.org/sites/default/…

Glad this out. Congrats to Mark Pepin. He found that mitochondrial NNT drives diastolic dysfunction in cardiometabolic HFpEF. This directed us to ROS-dependent mechanisms underlying HFpEF. More to come …ahajournals.org/doi/10.1161/CI…

Patients with heart failure and HFimpEF remain at high risk for cardiovascular events, but finerenone consistently reduces this risk without significant adverse effects. ja.ma/4jjmY0T orlyvardeny Muthu Vaduganathan Sanjiv J. Shah, MD Adriaan Voors clara saldarriaga

Maarten van den Hoogenhof found a specific way to improve cardiac function in RBM20 cardiomyopathy. CAMK2 inhibition might become the first tailored therapy for a Dilated Cardiomyopathy (after mavacamten for Hypertrophic Cardiomyopathy): biorxiv.org/content/10.110…

The #HeartFailureBeat will be back with a new episode in June. For now, enjoy this episode from the archives! ➡️ Get with the Guidelines! Contemporary Heart Failure Clinical Practice Updates from HFSA. Tune in for recommendations on how #palliativecare and HF go hand-in-hand.

Incredibly proud of Shelley Hall for representing the transplant community as a newly elected member of the inaugural #OPTN Board of Directors. A true leader shaping the future of organ transplantation. 👏🫀 #TransplantLeadership #OrganDonation

"Reassess. Reassess. And when you’re done—reassess again." Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA joins hosts Michael H. Beasley, MD and Priya Umapathi to explain why time-sensitive, serial reassessment is the cornerstone of cardiogenic shock care. 📊 Listen to the full #HFBeat episode on the 2025 ACC shock

New Paper🚨 ⁦Nature Reviews Cardiology⁩ "Mechano-energetic uncoupling in heart failure"explores how disrupted interactions between cardiac mechanics and mitochondrial energetics drive #HF ⁦⁦⁦COST Action EU-METAHEART⁩ 🙌🏻 ⁦⁦⁦⁦⁦William Harvey Research Institute⁩ nature.com/articles/s4156…

Are you an early stage researcher? Check out the newly released #FundingOpportunity for the #NIH Director’s New Innovator Award to fund exceptionally creative scientists proposing innovative, high-impact projects. Learn more: bit.ly/4jXnbXQ

💡“Call early and call often.” In our latest #HFBeat episode, Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA joins hosts Michael H. Beasley, MD and Priya Umapathi to share 10 key takeaways from the 2025 ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock. From staging to shock teams

Shout out and many congratulations to Silia DeFilippis MD FACC FAHA FHFSA Dharini Ramu Rebecca Cogswell Elena Marie and team for this important work 👏

With support from federal funding, researchers at Johns Hopkins have developed a new AI model that can identify patients likely to experience cardiac arrest. bit.ly/3I9wpD6 #ResearchSavesLives

New Episode of HF Beat: Gene Therapy in Genetic Cardiomyopathies 🧬 "Gene therapy isn’t science fiction anymore—it's here. 'We saw hearts shrink 40% in mass and troponins drop by 90%,' says Eric Adler on his groundbreaking Danon disease trial. Listen to how gene therapy is